

In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1-43. (cancelled).

44 (Currently amended). A peptide or polypeptide obtained from the armadillo domain of human  $\beta$ -catenin polypeptide which inhibits the interaction of human  $\beta$ -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from the group consisting of peptides or polypeptides ~~comprising~~ consisting of the sequences shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

45 (Currently amended). A peptide or polypeptide obtained from the armadillo domain of human  $\beta$ -catenin polypeptide which inhibits the interaction of human  $\beta$ -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from the group consisting of peptides or polypeptides ~~comprising~~ consisting of the sequences shown in SEQ ID NO: 6 having a mutation in Phe in position 253-30 or a mutation in His in position 37 or both; SEQ ID NO: 7 having a mutation in Arg in position 9 or a mutation in Lys in position 27 or both; SEQ ID NO: 8 having a mutation in Trp in position 32 or a mutation in Arg in position 36 or a mutation in Lys in position 39 or any combination of mutations thereof; SEQ ID NO: 9 having a mutation in Lys in position 5 or mutation in TRP in position 34 or a mutation in Arg in position 37 or any combination of mutations thereof; SEQ ID NO: 10 having a mutation in Lys in position 4; and SEQ ID NO: 11 having a mutation in Lys in position 6 or a mutation in Arg in position 28 or a mutation in Arg in position 40 or a mutation in His in position 41 or any combination of mutations thereof, wherein said mutation replaces the indicated amino acid with an aliphatic amino acid.

46 (canceled).

J:\sh-resp\bpd\BB-112-2doc.doc\DNB\la

47 (Currently amended). The ~~mutant~~ peptide or polypeptide according to claim ~~43 or 44~~, wherein said mutation replaces the indicated amino acid with alanine, valine, leucine or isoleucine.

48 (previously presented). The mutant according to claim 45, wherein said mutation replaces the indicated amino acid with alanine.

49 (canceled).

50 (Previously presented). The peptide of claim 47, wherein the effect is to inhibit the interaction of  $\beta$ -catenin and said transcription factor or tumor suppressor protein selected from the group of lymphoid enhancer-binding factor-1 (LEF-1), T cell transcription factor-1 (TCF-1), adenomatous polyposis coli 15 (APC 15) conductin, E-cadherin and 20 amino acid repeats of APC.